Gilead Sciences, Inc. (NASDAQ:GILD) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2023 1:30 PM ET Company Participants Dan O’Day - Chairman and CEO Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I’m Chris Schott at JPMorgan, and it’s my pleasure to be introducing Gilead today. From the Company, we’re going to have a presentation fr ...

Johnson & Johnson. (NYSE:JNJ) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 12:45 PM ET Company Participants Joaquin Duato - Chairman and CEO of J&J Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be hosting this fireside discussion today with Joaquin Duato, Chairman and CEO of J&J. So, Joaquin, Happy New Year. Great speaking with you today. I thought it might be a good way to start the conversat ...

Company and Industry Overview * **Company**: NVIDIA Corporation (NASDAQ: NVDA) * **Industry**: Healthcare, Artificial Intelligence, Drug Discovery * **Focus**: Accelerated computing, AI, and visualization platforms for healthcare, imaging, genomics, life sciences, drug discovery, and healthcare analytics. Key Points and Arguments * **Dual Computing Transitions**: NVIDIA is driving two simultaneous computing transitions - accelerated computing and AI. These transitions are enabling generative AI and driving platform shifts in software and applications like ChatGPT. * **Digital Biology Era**: Accelerated computing and generative AI are making possible the digital biology era, including advancements in genomics, omics fields, and cell imaging. * **Drug Discovery Revolution**: Generative AI is revolutionizing drug discovery by enabling the representation of drugs, biology, and chemistry in computers. This is leading to exponential growth in the computer-aided drug discovery (CAD) industry. * **BioNeMo Platform**: NVIDIA's BioNeMo platform provides services to develop, customize, and deploy AI foundation models for drug discovery. It offers large-scale, optimized, and easy-to-use training on proprietary data and a growing collection of pretrained models. * **Amgen Collaboration**: Amgen is using NVIDIA's BioNeMo and DGX Cloud to build generative AI models and search for novel human data insights for drug discovery. * **Recursion Partnership**: Recursion is using NVIDIA's BioNeMo to offer their foundation model, Phenom-Beta, for target and hit discovery in cellular data. * **MolMIM Model**: NVIDIA's own invented foundation model, MolMIM, uses a large language model to learn chemical space and achieve state-of-the-art performance in controlled molecular generation. * **CAD Industry Growth**: The CAD industry is expected to grow significantly, driven by advancements in digital biology, generative AI, and the need for personalized medicine. Other Important Content * **NVIDIA's Healthcare Strategy**: NVIDIA is focused on building deep domain expertise, domain-specific computing platforms, and a rich ecosystem of partners to accelerate the next generation of healthcare. * **Healthcare Market Opportunity**: The healthcare market presents significant opportunities for NVIDIA, with applications in drug discovery, medical imaging, and personalized medicine. * **NVIDIA's Investment Strategy**: NVIDIA is investing in companies that use their platform, enhance it, and expand it, with a focus on data and AI-driven companies. Conclusion NVIDIA's presentation at the J.P. Morgan Healthcare Conference highlights the company's leadership in accelerated computing, AI, and drug discovery. The BioNeMo platform and partnerships with leading companies are driving innovation in the healthcare industry and positioning NVIDIA for significant growth.

Amgen Inc. (NASDAQ:AMGN) J.P. Morgan 42nd Annual Healthcare Conference 2024 January 8, 2024 ET Company Participants Robert Bradway - Chairman & CEO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good morning, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be introducing Amgen today. From the company, we have Bob Bradway, the company's Chairman and CEO. Obviously, a very productive 2023 for the company and really looking forward to Bob's comments as we think about t ...

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Tim Wentworth - Chief Executive Officer Manmohan Mahajan - Interim Global Chief Financial Officer Conference Call Participants Lisa Gill - J.P. Morgan Lisa Gill Maybe it's just me. Oh, there we go. Good morning. My name is Lisa Gill, and I'm the healthcare services analyst with J.P. Morgan. It is with great pleasure this morning that I have with me Walgreens Boots Allian ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 11:15 AM ET Company Participants Jessica Fye - J.P. Morgan Conference Call Participants Reshma Kewalramani - Chief Executive Officer and President Jessica Fye Good morning, everyone. We're going to get started. My name is Jess Fye, I'm a Senior Biotech Analyst at J.P. Morgan, continuing the 42nd Annual Healthcare Conference this morning with Vertex. I'm joined by the Company's CEO, Reshma Kewalram ...

Bristol-Myers Squibb Company (NYSE:BMY) J.P. Morgan 42nd Annual Healthcare Conference Call January 8, 2024 10:30 AM ET Company Participants Chris Boerner - Chief Executive Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good morning, everybody. I'm Chris Schott at JPMorgan. It's great to see everybody back in person again this year for second year in a row. It's my pleasure this morning, though, to be introducing Bristol-Myers to again kick off the JPMorgan Healthcare Conference. F ...

CVS Health Corporation (NYSE:CVS) 42nd Annual J.P. Morgan Healthcare Conference January 8, 2023 10:30 AM ET Company Participants Karen Lynch - President & CEO Thomas Cowhey - CFO Conference Call Participants Lisa Gill - JPMorgan Chase Lisa Gill I don't think this is -- oh, now it's working, okay, and I'm loud. Karen Lynch Well, thank you, Lisa. Good morning, everyone, and Happy New Year. I'm really thrilled to be with you today to talk about CVS. And as Lisa said, I'm joined by our brand new CFO, Tom Cowhey ...

Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 11:00 AM ET Company Participants Adam Lenkowsky - CCO Conference Call Participants Chris Shibutani - Goldman Sachs Operator Hey, it’s the start of the year. Welcome to 2024. Anyway, my name is Chris Shibutani. I'm a member of the Goldman Sachs healthcare team. We are deeply grateful for the teams that were able to join us for this conference this very early date this year, and obviously, the point ...

Merck & Co., Inc. (NYSE:MRK) Goldman Sachs Healthcare C-Suite Unscripted Conference January 4, 2024 ET Company Participants Peter Dannenbaum - Head, IR Rob Davis - CEO Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani I suspect that people are going to be strolling in, but I don't like to penalize people who are on time, and let's try to stay on time. So let's get underway here. Welcome to what is by definition, in my opinion, the keynote presentation of this conference. We are th ...